MIM
BCAX

MetLife Investment Management’s Bicara Therapeutics BCAX Stock Holding History

MetLife Investment Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$365K Sell
18,360
-3,159
-15% -$54.4K ﹤0.01% 1906
2025
Q4 		$362K Hold
21,519
– – ﹤0.01% 1947
2025
Q3 		$340K Buy
+21,519
New +$241K ﹤0.01% 2013
2025
Q2 		– Sell
-12,163
Closed -$158K – 2938
2025
Q1 		$158K Hold
12,163
– – ﹤0.01% 2314
2024
Q4 		$212K Buy
+12,163
New +$253K ﹤0.01% 2277

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

MetLife Investment Management's BCAX Position: Q1 2026 in Review

MetLife Investment Management reduced its Bicara Therapeutics (BCAX) stake by 15% in Q1 2026, selling an estimated $54.4K and leaving 18,360 shares worth $365K. The position accounts for ﹤0.01% of the portfolio, ranked #1906.

MetLife Investment Management first reported a position in BCAX in Q4 2024 and has held it in 5 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • MetLife Investment Management held 18,360 shares of Bicara Therapeutics worth $365K as of Q1 2026.
  • MetLife Investment Management sold 3,159 Bicara Therapeutics shares in Q1 2026, an estimated $54.4K.
  • Bicara Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1906 holding.
  • MetLife Investment Management first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.